CME/CE

Faculty: Tina Q. Tan, MD Faculty: Yvonne Maldonado, MD This three-part educational activity reviews the burden of respiratory syncytial virus (RSV) and evidence-based strategies to prevent disease in infants and young children. Chapter 1 examines the epidemiology of RSV and outlines current prophylactic options, including maternal vaccination and the monoclonal antibodies nirsevimab (approved 2023...

Faculty: Tina Q. Tan, MD Faculty: Yvonne Maldonado, MD This three-part educational activity reviews the burden of respiratory syncytial virus (RSV) and evidence-based strategies to prevent disease in infants and young children. Chapter 1 examines the epidemiology of RSV and outlines current prophylactic options, including maternal vaccination and the monoclonal antibodies nirsevimab (approved 2023...

Faculty: Luca Busetto, MD Faculty: Kirsi H Pietiläinen, MD, PhD Expert faculty Drs. Luca Busetto and Kirsi H. Pietiläinen discuss the importance of early intervention in obesity management to prevent progression and obesity related complications. They examine the evolving therapeutic landscape, including GLP-1 and GIP-based medications like semaglutide and tirzepatide. The conversation highlights...

Faculty: Luca Busetto, MD Faculty: Kirsi H Pietiläinen, MD, PhD Expert faculty Drs. Luca Busetto and Kirsi H. Pietiläinen discuss the importance of early intervention in obesity management to prevent progression and obesity related complications. They examine the evolving therapeutic landscape, including GLP-1 and GIP-based medications like semaglutide and tirzepatide. The conversation highlights...

Host: Scott Kopetz, MD, PhD Host: Cathy Eng, MD, FACP This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Marc A. Riedl, MD, MS On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patients with HAE.

Faculty: Jose Rubio, MD Faculty: Jonathan M. Meyer In this Chairperson’s Perspective, Dr. Jose Rubio and Dr. Jonathan Meyer explore the evolving landscape of schizophrenia treatment through muscarinic receptor modulation. They compare the mechanisms of action, efficacy, and side effect profiles of muscarinic antipsychotics, such as xanomeline-trospium, with traditional dopamine D2 antagonists. The...

Host: Scott Kopetz, MD, PhD Host: Cathy Eng, MD, FACP This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

Host: Marc A. Riedl, MD, MS On-demand webcast with expert faculty presentation on addressing the unmet needs and optimizing treatment for hereditary angioedema (HAE), including long-term prophylaxis therapy, for patients with HAE.

Faculty: Jose Rubio, MD Faculty: Jonathan M. Meyer In this Chairperson’s Perspective, Dr. Jose Rubio and Dr. Jonathan Meyer explore the evolving landscape of schizophrenia treatment through muscarinic receptor modulation. They compare the mechanisms of action, efficacy, and side effect profiles of muscarinic antipsychotics, such as xanomeline-trospium, with traditional dopamine D2 antagonists. The...

Faculty: Linda Stein Gold, MD Faculty: April W. Armstrong, MD, MPH Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact patent compliance. However, the currently available oral small-molecule therapies apremilast and deucravacitinib have demo...

Faculty: Linda Stein Gold, MD Faculty: April W. Armstrong, MD, MPH Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact patent compliance. However, the currently available oral small-molecule therapies apremilast and deucravacitinib have demo...

Faculty: Jörg Latus, MD Faculty: Jürgen Floege, MD Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses on the new KDIGO proteinuria...

Faculty: Jörg Latus, MD Faculty: Jürgen Floege, MD Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses on the new KDIGO proteinuria...

Faculty: Scott Solomon, MD Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and build collaborative treatment plans. The session emphasizes early use of SGLT2 inhibitors and finerenone to reduce hospitalizations, improve q...

Faculty: Scott Solomon, MD Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and build collaborative treatment plans. The session emphasizes early use of SGLT2 inhibitors and finerenone to reduce hospitalizations, improve q...

Faculty: Joyce F. Liu, MD, MPH Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to de...

Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents d...

Faculty: Joyce F. Liu, MD, MPH Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents di...

Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents d...

Faculty: Joyce F. Liu, MD, MPH Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents di...

Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Faculty: Javed Butler, MD Faculty: Stephen J. Greene, MD, FACC, FHFSA For patients with heart failure with reduced ejection fraction (HFrEF), optimizing therapy is an important part of treatment and care. But not all patients may be reaching their treatment goals and can continue to face substantial residual risk despite the use of...

Faculty: Joyce F. Liu, MD, MPH Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to de...

Faculty: Kathleen Moore, MD, MS Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents d...

Faculty: Joyce F. Liu, MD, MPH Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents di...